EUROPE’S Coordination
Group for Mutual Recognition
and Decentralised Procedures
– Human (CMDh) has endorsed
the recommendation to suspend
the marketing authorisation
of methadone oral (by mouth)
solutions containing high molecular
weight povidone (K90).
The safety of the combination was
reviewed by the Pharmacovigilance
Risk Assessment Committee
following reports of serious adverse
events in Norway which led to the
suspension of methadone oral
solutions containing povidone K90
from the Norwegian market.
Oral tablets containing povidone
of lower molecular weight (e.g. K25
and K30) were successfully excreted
and would remain on the market.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.